Emerging Therapies for Ovarian Cancer - Chemotherapy Advisor

Emerging Therapies for Ovarian Cancer - Chemotherapy Advisor

Bevacizumab
Other Antiangiogenesis Agents
Poly(ADP-ribose) Polymerase Inhibitors
Other Novel Agents in Ovarian Cancer



 
printer-friendly (view all on one page): link

Cancers | Free Full-Text | Assessment of the Evolution of Cancer Treatment Therapies

Note: numerous references to ovarian cancer

Conclusions

This review has tried to summarize the history and evolution of the most common types of cancer

treatments available today, but also new therapies under study in the last years. In addition to surgery,

chemotherapy, radiation therapy, hyperthermia, photodynamic therapy or immunotherapy, new

therapies are now at different stages of development trying to decrease drug toxicity in health tissues

and increase efficacy by targeting tumor angiogenesis, by exploring cell and gene therapy, or by using

new nanostructures for diagnosis or therapeutic purposes. Nanotechnology is offering new products,

which either used alone, due to their intrinsic properties, or in combination with other biomolecules

(anti-tumoral drugs, folic acid, albumin, antibodies, aptamers) could be used to target cancer cells.

However, the history tells us that the fight against cancer is not an easy task. Many types of cancers

are able to resist to conventional therapies, and different combinations of drugs and therapies

(e.g., surgery together with radiotherapy and chemotherapy) are usually the only way to destroy

tumoral cells. This may be also true for the new therapies arriving now to the clinic. Much more

studies are required but these new ways of treatment are opening doors to hope for many patients

waiting for a successful therapy

Journal of Chemotherapy 2009 full access: What is the Benefit of 'Avastin' Combined with Chemotherapy in Patients - recurrent Ovarian, Primary ....

Journal of Chemotherapy 2009 full access: What is the Benefit of 'Avastin' Combined with Chemotherapy in Patients - recurrent Ovarian, Primary Peritoneal, Fallopian Tube Cancers.
Note: 64 patients in study; descriptive (stage 1C+); stage 1/11=4 pts; clear cell (2);endometrioid (3); mucinous (2);platinum resistant; side effects....(paper takes time to download)

Now's the time to find biomarkers on purpose -- Annals of Oncology

"Studies need to be conducted to determine the optimal design for using genome-wide profiling to identify putative biomarkers of drug response. To date, most biomarkers of drug response identified through genome-wide profiling have occurred through retrospective analysis of available tissue. To really progress this field, realistic planning for biomarker discovery and validation in clinical trials needs to be conducted. We, as clinical scientists, need to progress from only using convenient clinical cohorts to identify biomarkers to actually planning and following through with prospective clinical trials whose aims are to discover and/or validate putative biomarkers of drug response. To initiate a study without a realistic plan for discovery and validation reflects a lack of serious desire to find robust clinical predictors.^.... Until this becomes more commonplace, the genomic revolution will be focused on manuscript generation and investigator career development, leaving the benefit to patients nothing more than an unrealized dream."

full free access: Targeting the EGF Receptor for Ovarian Cancer Therapy

Note: numerous different treatments are discussed

full free access: Jan 2/2010 - Targeted Therapy in Ovarian Cancer

Review Article
Targeted Therapy in Ovarian Cancer
Lyndsay J. Willmott and John P. Fruehauf
Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA Academic Editor: Charles F. Levenback